Related Experiment Videos
Canadian Atrial Fibrillation Anticoagulation (CAFA) Study.
S J Connolly1, A Laupacis, M Gent
1Hamilton General Hospital, Ontario, Canada.
Journal of the American College of Cardiology
|August 1, 1991
Summary
Warfarin use in atrial fibrillation patients showed a trend toward reducing thromboembolism but increased bleeding risk. The study was stopped early, limiting definitive conclusions on warfarin
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Atrial fibrillation increases the risk of systemic thromboembolism.
- Warfarin is an anticoagulant used to prevent blood clots.
Purpose of the Study:
- To assess warfarin's efficacy in reducing systemic thromboembolism and its associated hemorrhage risk.
- To evaluate warfarin's safety profile in patients with atrial fibrillation.
Main Methods:
- Randomized, double-blind, placebo-controlled trial.
- Early termination due to concurrent study publications.
- 187 patients randomized to warfarin, 191 to placebo.
Main Results:
- Warfarin group: 43.7% of days within target INR range (2-3).
- Fatal or major bleeding: 2.5% annually (warfarin) vs. 0.5% (placebo).
- Primary outcome event cluster: 3.5% annually (warfarin) vs. 5.2% (placebo), a 37% relative risk reduction (p=0.17).
Conclusions:
- The study showed a trend towards reduced thromboembolic events with warfarin but a significantly higher bleeding risk.
- Early termination limited the statistical power to confirm warfarin's efficacy.
- Warfarin's risk-benefit profile requires careful consideration in atrial fibrillation management.